Megestrol acetate is supplied as a veterinary-grade active pharmaceutical ingredient for formulation into tablets, injectable suspensions, capsules, oral powders, granules, premixes, and non-aqueous solutions. The substance is the 17α-acetoxy-6-methylpregna-4,6-diene-3,20-dione; its CAS registry number is 595-33-5, its molecular formula is C₂₄H₃₂O₄, and its molecular mass is 384.51 g/mol. The compendial powder is an off-white to cream-colored crystalline solid with low aqueous solubility. The melting range is approximately 213–217 °C, which is well above the inlet air setpoints used in fluid-bed drying and above ordinary feed-processing temperatures. Three API grades are generally distinguished by dosage form: a non-micronized grade for granules and premixes, a micronized grade for low-dose tablets and hard capsules, and an aseptic-micronized grade for injectable suspensions. The grade designation is manufacturer-specific, but each grade is the same registered substance differentiated by particle-size distribution, endotoxin control, and residual solvent clearance.

Because the API is practically insoluble in water, particle-size reduction is the primary formulation lever rather than salt selection. The material is not a soluble salt; it is the neutral 17-acetate ester. This places dissolution rate and content uniformity under direct particle-size control. Compendial identification is performed by mid-infrared absorption spectrophotometry and HPLC retention time. Assay and related substances are determined by stability-indicating liquid chromatography under USP <621> or Ph. Eur. 2.2.29. The powder properties relevant to solid dosage design include bulk density, tapped density, Hausner ratio, and compressibility index under USP <616> Method I and Method II. Particle-size distribution is measured by laser diffraction under USP <429> or by optical microscopy under USP <776> for the non-micronized grade. Loss on drying is controlled under USP <731> or Ph. Eur. 2.2.32. Where an injectable grade is released, bacterial endotoxin and sterility tests are added as described below.

Crystallinity and Particle-Size Control Across Solid Oral, Injectable, and Premix Dosage Forms

Polymorphic form is controlled by X-ray powder diffraction under USP <941> because comminution can generate amorphous domains on particle surfaces. The amorphous fraction is a release-relevant variable because it alters water uptake and dissolution behavior in a low-solubility system. In a micronized grade, jet milling produces a particle population with a Dv50 often targeted in the single-digit micrometre range; the exact Dv90 is dossier-specific and is not assigned by a universal monograph. Laser diffraction under USP <429> is the standard release method for micronized material, while optical microscopy under USP <776> may be used for the coarser non-micronized grade. Bulk and tapped density are measured under USP <616> Method I and Method II. The Hausner ratio and compressibility index are used as release indicators because cohesive powder flow is the principal failure mode when the non-micronized grade is substituted into direct-compression blends. For wet granulation, pre-blending with a hydrophilic filler such as lactose monohydrate and a binder solution containing povidone K30 or pregelatinized starch is employed. The drying endpoint is controlled by loss on drying under USP <731> to avoid residual moisture-mediated hydrolysis of the 17-acetate ester. Low aqueous solubility means that content uniformity in low-dose tablet formats is especially sensitive to API particle size; dry blending without sufficient shear can leave intact agglomerates that pass assay but fail content uniformity testing under USP <905>.

How Does the C6-C7 Unsaturation Change Handling Relative to Medroxyprogesterone Acetate?

The structural distinction relevant to veterinary formulators is the presence of a 6-methyl-4,6-diene system in megestrol acetate rather than the 6α-methyl-4-ene system of medroxyprogesterone acetate. The additional C6–C7 double bond produces a slightly lower molecular mass and influences solid-state packing, melting behavior, and crystal habit. In practice, megestrol acetate is not automatically interchangeable with medroxyprogesterone acetate in a compounded preparation; the receptor-binding profile, duration of ovarian suppression, and approved indications differ among jurisdictions. The more saturated analogue has a different powder density and crystal habit, so direct substitution without particle-size re-characterization violates pharmaceutical equivalence. Table 2 summarizes the structural features relevant to API specification.

In tablet and hard-capsule processing, the low unit dose in many veterinary indications makes segregation the principal process risk, not chemical instability. The API is first de-agglomerated through an oscillating sieve or a cone mill before being loaded into a bin blender. A staged mixing sequence with lactose monohydrate, microcrystalline cellulose, and colloidal silicon dioxide is used; the glidant ratio is kept at or below 0.5% because excess silicon dioxide can coat the API and reduce dissolution. Magnesium stearate is added last and blended for a short final interval to avoid over-lubrication. Blend uniformity is tested under USP <905>. Bulk and tapped density values from USP <616> Method I and Method II are used to establish blend hold time. For capsule filling, the same powder blend is charged to an automatic capsule machine with dosing-disc or tamping-pin technology; fill weight is monitored in-process because megestrol acetate has no special electrostatic advantage over common excipients. Aqueous wet granulation is used where direct compression is not feasible; the binder solution is prepared with povidone K30, and drying is performed in a fluid-bed dryer with inlet air at 50–60 °C, below the melting range. Drying is confirmed by loss on drying under USP <731>.

When the API Is Specified for Injectable Suspensions or Non-Aqueous Solutions

Sterile injectable suspensions of megestrol acetate require an aseptic-micronized grade with bacterial endotoxin control under USP <85> or Ph. Eur. 2.6.14. The API is practically insoluble in water, so the finished preparation is usually a flocculated suspension or a non-aqueous solution. Terminal sterilization of an aqueous suspension may not be feasible for all formulations because heat can accelerate ester hydrolysis and particle aggregation; aseptic filtration of a suspension is not possible once the API is dispersed. Therefore the API is either sterilized as a dry powder by a validated method such as gamma irradiation or ethylene oxide, or it is crystallized and processed under aseptic conditions according to EU GMP Annex 1. Sterility testing follows USP <71> or Ph. Eur. 2.6.1. Particle-size distribution is qualified by laser diffraction under USP <429> to ensure that the suspended particle population remains within the syringeability specification. Wetting agents such as polysorbate 80 or sodium carboxymethylcellulose may be used to reduce particle flocculation and caking. The 17-acetate ester is sensitive to pH extremes; the formulation should avoid prolonged exposure to conditions outside approximately pH 4–7.5 at elevated temperature. For true solutions, non-aqueous vehicles or co-solvent systems are considered; published data for this specific configuration is limited, and aqueous solubility is well below that required for a single-phase injectable.

For oral powders, granules, and medicated premixes, the non-micronized grade is frequently selected because the carrier system provides sufficient bulk to mask cohesiveness. The API is loaded onto a carrier such as lactose monohydrate, corn starch, or wheat middlings by progressive geometric dilution; the premix is then mixed in a ribbon mixer or double-cone blender. Homogeneity is verified by assay of multiple sampling points, not by a single composite sample, because segregation along the blender shell is a known batch failure mode. The finished premix is passed through an oscillating sieve to break soft agglomerates before packaging. Moisture barrier packaging is required where stability data show that exposure to relative humidity above 60% increases hydrolytic degradation of the 17-acetate ester. Granulation for oral powder sachets uses the same aqueous binder approach as tablet manufacture, but the final granule particle-size distribution is tightened by analytical sieving under USP <786> to ensure uniform dispersion in drinking water or feed.

Residual Solvent, Elemental Impurity, and Stability-Indicating Controls

Release of the veterinary-grade API is performed under a stability-indicating HPLC method. Method validation demonstrates separation of the primary degradants: the 6-dehydro analogue, the free 17-hydroxy derivative, and oxidative ring-hydroxylated impurities. Residual solvent content is controlled under USP <467> or Ph. Eur. 2.4.24, and the solvent profile is aligned with ICH Q3C. Where ethanol or ethyl acetate is used in synthesis, class 3 residual solvent criteria apply; if dichloromethane is used in a crystallization step, a class 2 limit must be applied. Elemental impurities are assessed under USP <232> and <233> or ICH Q3D; palladium or platinum residues from catalytic hydrogenation are declared when the synthetic route includes a hydrogenation step. The test matrix in Table 1 lists the compendial methods most commonly included in a veterinary API specification.

Storage of the API is specified as protected from light and controlled at room temperature, with retest intervals assigned from long-term stability chambers according to ICH Q1A. The 17-acetate ester is not compatible with strong oxidizing agents or with acidic or alkaline granulating fluids held at elevated temperature for extended periods. Aluminum foil laminate packaging is recommended to limit moisture ingress, and the API should not be repackaged into high-moisture-transmission containers without revalidation. Batch release is performed under ICH Q7 and the applicable veterinary GMP provisions, with identical chromatographic identity standards applied to non-micronized, micronized, and aseptic-micronized grades.